# Implementing a coupled system of integrative ML modeling and data validation for elucidating microglial therapeutic targets in neurodegenerative disease

> **NIH NIH R44** · MODULO BIO, INC. · 2024 · $1,428,644

## Abstract

Project Summary/Abstract: ALS and FTD are fatal neurodegenerative diseases that presently have no cure.
To date, one focus area in ALS research has been developing model systems to characterize the condition,
with over 20 different ALS mouse models, and more recently, numerous iPSC based models, each gradually
contributing to our overall knowledge of the mechanisms behind neurodegeneration, and the contribution of the
neuro-immune interface. Despite the multitude of disease models, there is no overarching, computational
modeling framework for integrating disparate datasets, towards the goal of characterizing disease networks,
and identifying therapeutic targets. Moreover, while standard ML models for target prediction have become
ubiquitous in the biomedical sciences, they fail to learn causality, shedding little insight into underlying disease
etiology and failing to make effective target predictions. Our proposal’s long-term goal is to create a flexible
pipeline, applicable to ND diseases, to characterize the neuro-immune interface and its contribution to ND
etiology, to enable therapeutic intervention by creating an integrated workflow to identify ND microglial disease
networks in health, disease, and disease subsets. We will capitalize on existing experimental data as well as
internal iPSC based in vitro models, paired with a causal ML model. Each component of this workflow can work
independently, or can be linked to the other in a powerful ‘active learning’ framework, in which the ML model
makes predictions, the co-culture system validates or disproves the prediction, and in each such round the in
silico model is refined by integrating the new experimental data. Our causal machine learning model
characterizes ND neuro-immune networks from analysis of combined molecular, clinical, and functional data in
a multi-layered format with individual layers for ND disease state, data platform, and cell state analyzed
simultaneously to bolster confidence for inferences shared among numerous layers and identify unique, and
therapeutically relevant, network elements. We will focus initially on therapeutic interventions for ALS, followed
by related ND diseases also characterized in the network model. The objectives of this proposal are: (1) to
refine an in silico framework for data integration across NDs, microglial subsets, and heterogeneous
datasets/data platforms enabling a robust model for therapeutic target prediction and (2) to validate predicted
targets in our iPSC microglia and neuron co-culture system using in vitro perturbations (including
antisense-oligonucleotides and small molecules) and high-content imaging analysis. The central
hypothesis is that comprehensively integrating available data across public datasets and databases, ND
diseases, model species, data platforms, and tissue types, with data from our co-culture screening platform, in
a powerful mechanistic model, will enable elucidation of causal disease pathways, comparative analysis ...

## Key facts

- **NIH application ID:** 10930134
- **Project number:** 5R44MH135465-02
- **Recipient organization:** MODULO BIO, INC.
- **Principal Investigator:** Karen SACHS
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $1,428,644
- **Award type:** 5
- **Project period:** 2023-09-15 → 2025-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10930134

## Citation

> US National Institutes of Health, RePORTER application 10930134, Implementing a coupled system of integrative ML modeling and data validation for elucidating microglial therapeutic targets in neurodegenerative disease (5R44MH135465-02). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10930134. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*
